InvestorsHub Logo
Followers 2
Posts 485
Boards Moderated 0
Alias Born 03/22/2012

Re: Cytobeliever post# 27235

Sunday, 11/06/2022 4:52:53 PM

Sunday, November 06, 2022 4:52:53 PM

Post# of 27413
Cyto believer, I am surprised that you have been here for 10 years and never posted. I am also surprised that you did not see last weeks sepsis PR since you seem to think that they have abandoned sepsis.

NATIONAL INSTITUTES OF HEALTH GRANTS PHASE I SBIR AWARD TO CYTOSORBENTS TO TEST NOVEL POLYMERS FOR CYTOKINE AND ENDOTOXIN REMOVAL FROM SEPTIC PORCINE PLASMA
Goal is to advance new combined blood purification technologies to treat Gram negative sepsis – a deadly global killerPRINCETON, N.J., Oct. 31, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the National Institute of General Medical Sciences (NIGMS), a division of the U.S. National Institutes of Health, has granted CytoSorbents a Phase I Small Business Innovation Research (SBIR) award valued at $281,835. The eight-month award (Award #1R43GM144973-01) will allow CytoSorbents to test the ability of its novel and existing polymers to remove cytokines and lipopolysaccharide (LPS) endotoxin from septic porcine plasma. LPS endotoxin, released by Gram-negative bacteria such as E. coli, Salmonella, Pseudomonas, Klebsiella, and Legionella, is a well-known potent and deadly trigger of sepsis and septic shock by activating the immune system and generating a cytokine storm that can lead to massive, uncontrolled systemic inflammation, organ failure, and potentially death
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTSO News